• 1
    Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002; 52: 2347.
  • 2
    Hirata K, Sato T, Mukaiya M, et al. Results of 1001 pancreatic resections for invasive ductal adenocarcinoma of the pancreas. Arch Surg. 1997; 132: 771776; discussion, 7.
  • 3
    Bhutani MS, Hawes RH, Baron PL, et al. Endoscopic ultrasound guided fine needle aspiration of malignant pancreatic lesions. Endoscopy. 1997; 29: 854858.
  • 4
    Binmoeller KF, Thul R, Rathod V, et al. Endoscopic ultrasound-guided, 18-gauge, fine needle aspiration biopsy of the pancreas using a 2.8 mm channel convex array echoendoscope. Gastrointest Endosc. 1998; 47: 121127.
  • 5
    Voss M, Hammel P, Molas G, et al. Value of endoscopic ultrasound guided fine needle aspiration biopsy in the diagnosis of solid pancreatic masses. Gut. 2000; 46: 244249.
  • 6
    Suits J, Frazee R, Erickson RA. Endoscopic ultrasound and fine needle aspiration for the evaluation of pancreatic masses. Arch Surg. 1999; 134: 639642; discussion, 42–43.
  • 7
    Di Stasi M, Lencioni R, Solmi L, et al. Ultrasound-guided fine needle biopsy of pancreatic masses: results of a multicenter study. Am J Gastroenterol. 1998; 93(8): 13291333.
    Direct Link:
  • 8
    Mueller PR. Pancreatic biopsy: striving for excellence. Radiology. 1993; 187: 1516.
  • 9
    Brandt KR, Charboneau JW, Stephens DH, Welch TJ, Goellner JR. CT- and US-guided biopsy of the pancreas. Radiology. 1993; 187: 99104.
  • 10
    Ho JJ, Kim YS. Serological pancreatic tumor markers and the MUC1 apomucin. Pancreas. 1994; 9: 674691.
  • 11
    Devine PL, McKenzie IF. Mucins: structure, function, and associations with malignancy. Bioessays. 1992; 14(9): 619625.
  • 12
    Strous GJ, Dekker J. Mucin-type glycoproteins. Crit Rev Biochem Mol Biol. 1992; 27: 5792.
  • 13
    Ho SB, Niehans GA, Lyftogt C, et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res. 1993; 53: 641651.
  • 14
    Osako M, Yonezawa S, Siddiki B, et al. Immunohistochemical study of mucin carbohydrates and core proteins in human pancreatic tumors. Cancer. 1993; 71: 21912199.
  • 15
    Masaki Y, Oka M, Ogura Y, et al. Sialylated MUC1 mucin expression in normal pancreas, benign pancreatic lesions, and pancreatic ductal adenocarcinoma. Hepatogastroenterology. 1999; 46: 22402245.
  • 16
    Terada T, Ohta T, Sasaki M, Nakanuma Y, Kim YS. Expression of MUC apomucins in normal pancreas and pancreatic tumours. J Pathol. 1996; 180: 160165.
  • 17
    Monges GM, Mathoulin-Portier MP, Acres RB, et al. Differential MUC 1 expression in normal and neoplastic human pancreatic tissue. An immunohistochemical study of 60 samples. Am J Clin Pathol. 1999; 112: 635640.
  • 18
    Manne U, Weiss HL, Grizzle WE. Racial differences in the prognostic usefulness of MUC1 and MUC2 in colorectal adenocarcinomas. Clin Cancer Res. 2000; 6: 40174025.
  • 19
    Kim YS, Gum J Jr., Brockhausen I. Mucin glycoproteins in neoplasia. Glycoconj J. 1996; 13: 693707.
  • 20
    Kim YS, Gum J Jr., Crawley SC, Deng G, Ho JJ. Mucin gene and antigen expression in biliopancreatic carcinogenesis. Ann Oncol. 1999; 10(Suppl 4): 5155.
  • 21
    Hendrix E, Hewetson A, Mansharamani M, Chilton BS. Oviductin (Muc9) is expressed in rabbit endocervix. Endocrinology. 2001; 142: 2151.
  • 22
    Melnick M, Chen H, Zhou Y, Jaskoll T. An alternatively spliced Muc10 glycoprotein ligand for putative L-selectin binding during mouse embryonic submandibular gland morphogenesis. Arch Oral Biol. 2001; 46: 745757.
  • 23
    Williams SJ, McGuckin MA, Gotley DC, Eyre HJ, Sutherland GR, Antalis TM. Two novel mucin genes down-regulated in colorectal cancer identified by differential display. Cancer Res. 1999; 59: 40834089.
  • 24
    Williams SJ, Wreschner DH, Tran M, Eyre HJ, Sutherland GR, McGuckin MA. Muc13, a novel human cell surface mucin expressed by epithelial and hemopoietic cells. J Biol Chem. 2001; 276: 1832718336.
  • 25
    Patton S, Gendler SJ, Spicer AP. The epithelial mucin, MUC1, of milk, mammary gland and other tissues. Biochim Biophys Acta. 1995; 1241: 407423.
  • 26
    Balague C, Gambus G, Carrato C, et al. Altered expression of MUC2, MUC4, and MUC5 mucin genes in pancreas tissues and cancer cell lines. Gastroenterology. 1994; 106: 10541061.
  • 27
    Byrd JC, Ho JJ, Lamport DT, et al. Relationship of pancreatic cancer apomucin to mammary and intestinal apomucins. Cancer Res. 1991; 51: 10261033.
  • 28
    Kim GE, Bae HI, Park HU, et al. Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas. Gastroenterology. 2002; 123: 10521060.
  • 29
    Luttges J, Zamboni G, Longnecker D, Kloppel G. The immunohistochemical mucin expression pattern distinguishes different types of intraductal papillary mucinous neoplasms of the pancreas and determines their relationship to mucinous noncystic carcinoma and ductal adenocarcinoma. Am J Surg Pathol. 2001; 25: 942948.
  • 30
    Hanski C, Riede E, Gratchev A, et al. MUC2 gene suppression in human colorectal carcinomas and their metastases: in vitro evidence of the modulatory role of DNA methylation. Lab Invest. 1997; 77: 685695.
  • 31
    Wesseling J, van der Valk SW, Hilkens J. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell. 1996; 7: 565577.
  • 32
    Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol. 1995; 129: 255265.
  • 33
    van de Wiel-van Kemenade E, Ligtenberg MJ, de Boer AJ, et al. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J Immunol. 1993; 151: 767776.
  • 34
    Ligtenberg MJ, Buijs F, Vos HL, Hilkens J. Suppression of cellular aggregation by high levels of episialin. Cancer Res. 1992; 52: 23182324.
  • 35
    Hruban RH, van Mansfeld AD, Offerhaus GJ, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol. 1993; 143: 545554.
  • 36
    Mora J, Puig P, Boadas J, et al. K-ras gene mutations in the diagnosis of fine-needle aspirates of pancreatic masses: prospective study using two techniques with different detection limits. Clin Chem. 1998; 44: 22432248.
  • 37
    Pinto MM, Emanuel JR, Chaturvedi V, Costa J. Ki-ras mutations and the carcinoembryonic antigen level in fine needle aspirates of the pancreas. Acta Cytol. 1997; 41: 427434.
  • 38
    Tada M, Komatsu Y, Kawabe T, et al. Quantitative analysis of K-ras gene mutation in pancreatic tissue obtained by endoscopic ultrasonography-guided fine needle aspiration: clinical utility for diagnosis of pancreatic tumor. Am J Gastroenterol. 2002; 97: 22632270.
    Direct Link:
  • 39
    Shibata D, Almoguera C, Forrester K, et al. Detection of c-K-ras mutations in fine needle aspirates from human pancreatic adenocarcinomas. Cancer Res. 1990; 50: 12791283.
  • 40
    Villanueva A, Reyes G, Cuatrecasas M, et al. Diagnostic utility of K-ras mutations in fine-needle aspirates of pancreatic masses. Gastroenterology. 1996; 110: 15871594.
  • 41
    Scarpa A, Capelli P, Villaneuva A, et al. Pancreatic cancer in Europe: Ki-ras gene mutation pattern shows geographical differences. Int J Cancer. 1994; 57: 167171.
  • 42
    Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res. 1994; 54: 35683573.
  • 43
    Yanagisawa A, Ohtake K, Ohashi K, et al. Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer Res. 1993; 53: 953956.